These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31691354)

  • 21. A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients.
    Jasiak-Panek NM; Wenzler E; Patel S; Thielke JJ; Progar K; Patel S; Brandt S; Huang YJ; Benedetti E; West-Thielke PM
    Clin Transplant; 2019 Aug; 33(8):e13640. PubMed ID: 31206808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients.
    Heavner MS; Tichy EM; Yazdi M; Formica RN; Kulkarni S; Emre S
    Am J Health Syst Pharm; 2013 Sep; 70(17):1507-12. PubMed ID: 23943182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients.
    Huang CT; Shu KH; Ho HC; Wu MJ
    Transplant Proc; 2016; 48(6):1978-80. PubMed ID: 27569931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM
    Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.
    Wissing KM; Abramowicz D; Weekers L; Budde K; Rath T; Witzke O; Broeders N; Kianda M; Kuypers DRJ
    Am J Transplant; 2018 Jul; 18(7):1726-1734. PubMed ID: 29337426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation.
    Gaynor JJ; Ciancio G; Guerra G; Sageshima J; Roth D; Goldstein MJ; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
    Transpl Int; 2016 Feb; 29(2):216-26. PubMed ID: 26442829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial.
    Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K
    Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation.
    Žilinská Z; Dedinská I; Breza J; Laca L
    Transplant Proc; 2016 Oct; 48(8):2637-2643. PubMed ID: 27788794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time?
    Falconer SJ; Peagam WR; Oniscu GC
    Transplant Proc; 2015; 47(6):1741-5. PubMed ID: 26293044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protocol-based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients-A single-center experience with a large African American population.
    Elmaasarani Z; Mardis C; Gylten L; Taber DJ; Fleming J; Patel N; Baliga P; Rao V; Rohan V; DuBay D; Pilch NA
    Clin Transplant; 2019 Oct; 33(10):e13701. PubMed ID: 31461791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.